On December 11, Syneron Bio, a company focused on the development of macrocyclic peptide drugs, declared that it had successfully concluded its Series A and Series A+ funding rounds in succession, amassing a total of nearly US$100 million. This financing round was spearheaded by AstraZeneca, the AstraZeneca CICC Healthcare Fund, and prominent healthcare funds. It also saw participation from a range of institutions, including the Pfizer Biotech Development Investment Fund, Hillhouse Capital, 5Y Capital, Sinovation Ventures, Legend Capital, Gree Industrial Investment, and Xinneng Venture Capital. Syneron Bio stands as a biotechnology firm committed to the creation of innovative macrocyclic peptide drugs. Leveraging its proprietary Synova™ platform technology, the company has built an extensive pipeline of macrocyclic peptide drugs, presenting groundbreaking therapeutic options for the global oncology, autoimmune disease, and rare disease sectors.